

Get the Inside scoop on why Generex's Insulin Spray is at the front of the pack!

Generex's insulin spray "Oralin" is much closer to commercialization While "Exubera" is put on hold for 2002.

Today's Wall Street Journal reports that GlaxoSmithKline (NYSE: GSK), the makers of the popular Type 2 drug Avandia, is about to sign an agreement with Nobex Corp. to develop an oral insulin drug. While this development is interesting the real news is what's missing from the article. While the article mentions Emisphere Technologies (NASDAQ:EMIS) and Model portfolio member Generex Biotechnology (NASDAQ:GNBT) as other companies who also in the race, NO mention is made of Exubera (Exubera is Pfizer's (NYSE:PFE) attempt at inhaled insulin) or Aradigm (NASDAQ:ARDM) who's partnered with Model Portfolio member Novo Nordisk (NYSE:NVO).

[Could it be that the street has finally awakened to the fact that insulin that's absorbed through the lungs just won't fly? Something that Diabetic Investor has been saying for several years.](#)

There's no question that should someone successfully develop a non-injectable form of insulin that it would be a major commercial success. Diabetes is growing at epidemic rates and insulin therapy is gaining greater acceptance in the medical community. The fact of the matter is, while oral medications such as Avandia do a good job of controlling Type 2 diabetes, oral medications alone often are not the answer. The American Diabetes Association (ADA) estimates that there are over 1 million people with Type 1 (insulin dependent) diabetes. However, the ADA also estimates that there are nearly 15 million people with Type 2 (non-insulin dependent) diabetes. Of those 15 million Type 2's Diabetic Investor estimates that there are nearly 3 to 4 million Type 2's who use insulin as part of their daily treatment regiment. Many in the industry also believe that more Type 2's would use insulin if it did not have to inject. The fact is with the majority of Type 2's are treated by a primary care physician who is often reluctant to prescribe insulin to their patients because it must be injected.

In a perfect world it would be great if insulin was available in a pill. However, there are several significant hurdles to overcome before this ever becomes a reality. Progress is being made but we are still years away.

Much closer to commercialization is Generex's insulin spray called Oralin. Unlike other attempts at oral insulin, Oralin is not absorbed in the lungs; it's absorbed in the mouth. Oralin offers another advantage over its competitors in that its delivery device is simple to operate and looks much like an asthma inhaler. No special instructions, the patient doesn't have to carry a cumbersome device, doesn't have to wait to be breathing "properly" – just put the device up to the mouth, push and put it back in their pocket or purse. It's that simple.

To date all studies indicate that Oralin is both safe and effective, something that cannot be said about its competitors. Currently all Phase II trials for Oralin have been completed and the company expects to begin Phase III trials sometime in the fall. Generex is also partnered with Model Portfolio member Eli Lilly (NYSE:LLY).

David Kliff
Publisher
Diabetic Investor
800-783-3712
847-634-4777
847-634-4646 Fax
dkliff@diabeticinvestor.com